| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 2
Cisplatin treatment in EMT6 murine breast cancer cells: Impact on cell viability and molecular pathways
1 Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul, Türkiye, 2 Istanbul Medipol University, Graduate School of Health Sciences, Department of Neuroscience, Istanbul, Türkiye, 3 Istanbul Medipol University, School of Medicine, Department of Medical Biology and Genetics, Istanbul, Türkiye
DOI :
10.23893/1307-2080.APS6323